Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has been given an average recommendation of “Hold” by the thirteen ratings firms that are currently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $20.20.

Several research analysts have commented on INO shares. HC Wainwright set a $13.00 target price on Inovio Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, July 7th. Zacks Investment Research upgraded Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 target price for the company in a research note on Tuesday, July 11th. Aegis restated a “buy” rating and issued a $14.00 target price on shares of Inovio Pharmaceuticals in a research note on Tuesday, July 18th. BidaskClub downgraded Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Finally, Maxim Group set a $12.00 target price on Inovio Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 9th.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://www.watchlistnews.com/inovio-pharmaceuticals-inc-ino-given-average-rating-of-hold-by-analysts/1650109.html.

Several institutional investors and hedge funds have recently modified their holdings of INO. BlueCrest Capital Management Ltd bought a new stake in shares of Inovio Pharmaceuticals during the 2nd quarter valued at about $107,000. PNC Financial Services Group Inc. boosted its position in shares of Inovio Pharmaceuticals by 5.0% during the 2nd quarter. PNC Financial Services Group Inc. now owns 21,000 shares of the biopharmaceutical company’s stock valued at $164,000 after acquiring an additional 1,000 shares during the last quarter. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Inovio Pharmaceuticals during the 2nd quarter valued at about $171,000. Bank of America Corp DE boosted its position in shares of Inovio Pharmaceuticals by 14.6% during the 1st quarter. Bank of America Corp DE now owns 28,256 shares of the biopharmaceutical company’s stock valued at $188,000 after acquiring an additional 3,605 shares during the last quarter. Finally, OxFORD Asset Management LLP bought a new stake in shares of Inovio Pharmaceuticals during the 2nd quarter valued at about $194,000. Hedge funds and other institutional investors own 24.83% of the company’s stock.

Shares of Inovio Pharmaceuticals (INO) traded down 4.98% during midday trading on Wednesday, hitting $5.92. 1,628,410 shares of the stock were exchanged. Inovio Pharmaceuticals has a 1-year low of $5.28 and a 1-year high of $9.86. The stock’s 50-day moving average price is $6.22 and its 200-day moving average price is $6.64. The firm’s market capitalization is $534.14 million.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.08. The company had revenue of $20.41 million during the quarter, compared to the consensus estimate of $16.29 million. Inovio Pharmaceuticals had a negative return on equity of 63.67% and a negative net margin of 153.46%. The firm’s quarterly revenue was up 229.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.26) EPS. On average, analysts forecast that Inovio Pharmaceuticals will post ($0.95) EPS for the current year.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.